Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Seeburger, Jeffrey L.a; 1 | Holder, Daniel J.a; 1 | Combrinck, Marcb; c | Joachim, Catharineb | Laterza, Omara | Tanen, Michaela | Dallob, Aimeea | Chappell, Dereka | Snyder, Karena | Flynn, Marya | Simon, Adama | Modur, Vijaya | Potter, William Z.a | Wilcock, Gordonb | Savage, Mary J.a; * | Smith, A. Davidb; d
Affiliations: [a] Merck Research Laboratories, Merck & Co., Inc., Whitehouse Station, NJ, USA | [b] OPTIMA, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK | [c] Current address: University of Cape Town, Groote Schuur Hospital, Cape Town, ZA | [d] OPTIMA, Department of Pharmacology, Mansfield Rd., Oxford, UK
Correspondence: [*] Correspondence to: Dr. Mary J. Savage, Molecular Biomarkers & Diagnostics, Merck Research Laboratories, RY50-1D-131, 126 E. Lincoln Avenue, Rahway, NJ 07065, USA. Tel.: +1 732 594 1089; E-mail: [email protected].
Note: [1] These authors contributed equally to this work.
Abstract: Cerebrospinal fluid (CSF) amyloid-β (Aβ) and tau have been studied as markers of Alzheimer's disease (AD). Combined Aβ42 and t-tau distinguishes AD from healthy controls with a sensitivity and specificity (sens/spec) near 89% across studies. This study examined these markers in the homogeneous OPTIMA cohort, using extensive longitudinal follow up and postmortem evaluation to confirm clinicopathological status. Baseline CSF was analyzed from 227 participants with AD (97% autopsy-confirmed), mild cognitive impairment (MCI; 73% confirmed), other dementia syndrome (ODS; 100% confirmed), and controls (CTL; 27% confirmed, follow up approximately 9–13 years). Biomarker concentrations were analyzed using validated ELISAs. AD patients had lower CSF Aβ42 and higher t-tau, p-tau, t-tau/Aβ42, and t-tau/Aβ40 compared to CTLs, with MCI intermediate. CTL and MCI participants who progressed to AD demonstrated more AD-like profiles. Aβ40, sAβPPα, and sAβPPβ were lower in AD compared to CTL. High-level discriminators of AD from CTL were t-tau/Aβ40 (AUROC 0.986, sens/spec of 92%/94%), p-tau/Aβ42 (AUROC 0.972, sens/spec of 94%/90%), and Aβ42 (AUROC 0.941, sens/spec of 88%). For discriminating AD from ODS, p-tau/Aβ42 demonstrated sens/spec of 88%/100% (95%/86% at the AD versus CTL cutoff) and Aβ42 demonstrated sens/spec of 84%/100% (88%/100% at the AD versus CTL cutoff). In a well-characterized, homogeneous population, a single cutoff for baseline CSF Aβ and tau markers can distinguish AD with a high level of sens/spec compared to other studies. It may be important to characterize sources of demographic and biological variability to support the effective use of CSF diagnostic assays in the broader AD population.
Keywords: Alzheimer's disease, amyloid-β, biomarker, cerebrospinal fluid, frontotemporal dementia, mild cognitive impairment, postmortem examination, tau
DOI: 10.3233/JAD-141725
Journal: Journal of Alzheimer's Disease, vol. 44, no. 2, pp. 525-539, 2015
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]